TY  - JOUR

T1  - 484 Dupilumab provides clinically meaningful improvement in atopic dermatitis (AD) signs and symptoms and quality of life (QoL) in children with severe AD: Results from the LIBERTY AD PEDS phase 3 clinical trial

JO  - Journal of Investigative Dermatology

PY  - 2021/05/01

AU  - Paller A

AU  - Cork MJ

AU  - Marcoux D

AU  - Zhang H

AU  - Chuang C

AU  - Zhang A

AU  - Chao J

ED  - 

DO  - DOI: 10.1016/j.jid.2021.02.508

VL  - 141

IS  - 5

SP  - s84

Y2  - 2024/12/22

ER  -